Senolytics: Potential for Alleviating Diabetes and Its Complications
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
Therapeutics that target cellular senescence, including novel “senolytic” compounds, hold significant promise for treating or preventing obesity-induced metabolic dysfunction, type 2 diabetes, and the multiple complications of diabetes and obesity. Senolytics selectively clear senescent cells, which accumulate with aging and obesity and represent a fundamental mechanism of aging that contributes to metabolic dysfunction and diabetes pathogenesis. In addition to improving metabolic function, targeting senescent cells holds promise as a preventive strategy to reduce the incidence and severity of diabetes complications. The intermittent administration schedule used for senolytic therapy may confer benefits in terms of improving adherence and limiting adverse effects. It is necessary to design effective clinical trials that will safely translate discoveries from preclinical models into human studies that may pave the way for a novel therapeutic class for treating obesity, diabetes, and their complications. In this review, we outline what is known regarding the role of cellular senescence in the pathogenesis of type 2 diabetes and its complications, present evidence from preclinical models that targeting cellular senescence is beneficial, review senolytic drugs, and outline the features of clinical trials investigating the role of targeting senescent cells for diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cellular senescence: from physiology to pathology
Muñoz-Espín, D., & Serrano, M. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3823 · Cited by 2,818
The Achilles' heel of senescent cells: from transcriptome to senolytic drugs
Zhu, Y., Tchkonia, T., Pirtskhalava, T., Gower, A. C., Ding, H., Giorgadze, N., Palmer, A. K., Ikeno, Y., Hubbard, G. B., Lenburg, M., et al. (2015) · Aging Cell · doi:10.1111/acel.12344 · Cited by 2,584
Self-citationSenolytics improve physical function and increase lifespan in old age
Xu, M., Pirtskhalava, T., Farr, J. N., Weigand, B. M., Palmer, A. K., Weivoda, M. M., Inman, C. L., Ogrodnik, M. B., Hachfeld, C. M., Fraser, D. G., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0092-9 · Cited by 2,287
Self-citationA complex secretory program orchestrated by the inflammasome controls paracrine senescence
Acosta, J. C., Banito, A., Wuestefeld, T., Georgilis, A., Janich, P., Morton, J. P., Athineos, D., Kang, T.-W., Lasitschka, F., Andrulis, M., et al. (2013) · Nature Cell Biology · doi:10.1038/ncb2784 · Cited by 2,278 · cited 1×
“Once senescent cells form, the SASP can spread senescence in a paracrine or endocrine manner to previously normal local or distant cells (2, 9, 12-14).”
BackgroundAn Essential Role for Senescent Cells in Optimal Wound Healing through Secretion of PDGF-AA
Demaria, M., Ohtani, N., Youssef, S. A., Rodier, F., Toussaint, W., Mitchell, J. R., Laberge, R.-M., Vijg, J., Van Steeg, H., Dollé, M. E. T., et al. (2014) · Developmental Cell · doi:10.1016/j.devcel.2014.11.012 · Cited by 2,045
Senescence of Activated Stellate Cells Limits Liver Fibrosis
Krizhanovsky, V., Yon, M., Dickins, R. A., Hearn, S., Simon, J., Miething, C., Yee, H., Zender, L., & Lowe, S. W. (2008) · Cell · doi:10.1016/j.cell.2008.09.015 · Cited by 2,027
Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice
Chang, J., Wang, Y., Shao, L., Laberge, R.-M., Demaria, M., Campisi, J., Janakiraman, K., Sharpless, N. E., Ding, S., Feng, W., et al. (2016) · Nature Medicine · doi:10.1038/nm.4010 · Cited by 1,819 · cited 1×
“Subsequently, additional senolytic drugs including navitoclax (ABT263) (16, 39), and fisetin (40) were discovered.”
BackgroundInk4a/Arf expression is a biomarker of aging
Krishnamurthy, J., Torrice, C., Ramsey, M. R., Kovalev, G. I., Al-Regaiey, K., Su, L., & Sharpless, N. E. (2004) · Journal of Clinical Investigation · doi:10.1172/jci22475 · Cited by 1,486
Hickson, L. J., Langhi Prata, L. G. P., Bobart, S. A., Evans, T. K., Giorgadze, N., Hashmi, S. K., Herrmann, S. M., Jensen, M. D., Jia, Q., Jordan, K. L., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.08.069 · Cited by 1,383
Self-citationSenolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study
Justice, J. N., Nambiar, A. M., Tchkonia, T., LeBrasseur, N. K., Pascual, R., Hashmi, S. K., Prata, L., Masternak, M. M., Kritchevsky, S. B., Musi, N., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2018.12.052 · Cited by 1,261 · cited 3×
“In an open-label pilot study of patients with idiopathic pulmonary fibrosis, senolytic (D + Q) therapy improved physical function, including 6-minute walk distance, gait speed, chair stand time, and the Short Physical Performance Battery (54).”
BackgroundResultSelf-citationSenolytic drugs: from discovery to translation
Kirkland, J. L., & Tchkonia, T. (2020) · Journal of Internal Medicine · doi:10.1111/joim.13141 · Cited by 1,227
Self-citationTargeting cellular senescence prevents age-related bone loss in mice
Farr, J. N., Xu, M., Weivoda, M. M., Monroe, D. G., Fraser, D. G., Onken, J. L., Negley, B. A., Sfeir, J. G., Ogrodnik, M. B., Hachfeld, C. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4385 · Cited by 1,182
Self-citationSenescence and the SASP: many therapeutic avenues
Birch, J., & Gil, J. (2020) · Genes & Development · doi:10.1101/gad.343129.120 · Cited by 1,177 · cited 2×
“Some senescent cells become enlarged, in part due to increased protein synthesis, and undergo changes in gene expression to produce the senescence-associated secretory phenotype, or SASP, which includes inflammatory factors, matrix remodeling enzymes, chemokines, cytokines, bioactive lipids (prostenoids, bradykines, c…”
BackgroundZhu, Y., Tchkonia, T., Fuhrmann‐Stroissnigg, H., Dai, H. M., Ling, Y. Y., Stout, M. B., Pirtskhalava, T., Giorgadze, N., Johnson, K. O., Giles, C. B., et al. (2016) · Aging Cell · doi:10.1111/acel.12445 · Cited by 1,148
Self-citationFat tissue, aging, and cellular senescence
Tchkonia, T., Morbeck, D. E., Von Zglinicki, T., Van Deursen, J., Lustgarten, J., Scrable, H., Khosla, S., Jensen, M. D., & Kirkland, J. L. (2010) · Aging Cell · doi:10.1111/j.1474-9726.2010.00608.x · Cited by 1,094 · cited 3×
“Adipose tissue can constitute a significant reservoir of senescent cells, particularly in obesity and diabetes (4, 5, 18).”
BackgroundSelf-citationCellular senescence drives age-dependent hepatic steatosis
Ogrodnik, M., Miwa, S., Tchkonia, T., Tiniakos, D., Wilson, C. L., Lahat, A., Day, C. P., Burt, A., Palmer, A., Anstee, Q. M., et al. (2017) · Nature Communications · doi:10.1038/ncomms15691 · Cited by 1,044
Self-citationCellular senescence: a translational perspective
Kirkland, J. L., & Tchkonia, T. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.04.013 · Cited by 1,013
Self-citationZhu, Y., Doornebal, E. J., Pirtskhalava, T., Giorgadze, N., Wentworth, M., Fuhrmann-Stroissnigg, H., Niedernhofer, L. J., Robbins, P. D., Tchkonia, T., & Kirkland, J. L. (2017) · Aging · doi:10.18632/aging.101202 · Cited by 757
Self-citationRoos, C. M., Zhang, B., Palmer, A. K., Ogrodnik, M. B., Pirtskhalava, T., Thalji, N. M., Hagler, M., Jurk, D., Smith, L. A., Casaclang‐Verzosa, G., et al. (2016) · Aging Cell · doi:10.1111/acel.12458 · Cited by 738
Self-citationTargeting senescent cells alleviates obesity-induced metabolic dysfunction
Palmer, A. K., Xu, M., Zhu, Y., Pirtskhalava, T., Weivoda, M. M., Hachfeld, C. M., Prata, L. G., van Dijk, T. H., Verkade, E., Casaclang‐Verzosa, G., et al. (2019) · Aging Cell · doi:10.1111/acel.12950 · Cited by 658
Self-citationMoiseeva, O., Deschênes‐Simard, X., St‐Germain, E., Igelmann, S., Huot, G., Cadar, A. E., Bourdeau, V., Pollak, M. N., & Ferbeyre, G. (2013) · Aging Cell · doi:10.1111/acel.12075 · Cited by 654
Pharmacokinetics and bioavailability of quercetin glycosides in humans
Graefe, E. U., Wittig, J., Mueller, S., Riethling, A., Uehleke, B., Drewelow, B., Pforte, H., Jacobasch, G., Derendorf, H., & Veit, M. (2001) · The Journal of Clinical Pharmacology · doi:10.1177/00912700122010366 · Cited by 649 · cited 2×
“that arise through continuous drug occupancy of a receptor or inhibition of an enzyme (45, 46).”
BackgroundTargeting senescent cells enhances adipogenesis and metabolic function in old age
Xu, M., Palmer, A. K., Ding, H., Weivoda, M. M., Pirtskhalava, T., White, T. A., Sepe, A., Johnson, K. O., Stout, M. B., Giorgadze, N., et al. (2015) · eLife · doi:10.7554/elife.12997 · Cited by 604 · cited 3×
“In addition to these metabolic benefits, some complications of diabetes were also improved or prevented in obese mice, including microalbuminuria, diastolic cardiac dysfunction, hepatic steatosis, and obesity-induced anxiety (18, 27, 55, 56).”
BackgroundSelf-citationCancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis
Noto, H., Goto, A., Tsujimoto, T., & Noda, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033411 · Cited by 566 · cited 1×
“In addition, metformin is known to alleviate diabetic complications and metabolic syndrome, and may confer lower cancer risk in diabetic patients (63).”
BackgroundThe Clinical potential of Senolytic Drugs
Kirkland, J. L., Tchkonia, T., Zhu, Y., Niedernhofer, L. J., & Robbins, P. D. (2017) · Journal of the American Geriatrics Society · doi:10.1111/jgs.14969 · Cited by 539 · cited 1×
“As an example of the durability of response to senolytic therapy, positive effects of one round of senolytic treatment on the mobility of mice that had undergone radiation of one hind leg lasted for at least 7 months, despite the elimination half-life of each drug being only a few hours (15, 44-46).”
BackgroundSelf-citationObesity-Induced Cellular Senescence Drives Anxiety and Impairs Neurogenesis
Ogrodnik, M., Zhu, Y., Langhi, L. G. P., Tchkonia, T., Krüger, P., Fielder, E., Victorelli, S., Ruswhandi, R. A., Giorgadze, N., Pirtskhalava, T., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2018.12.008 · Cited by 536
Self-citationImpaired adipogenesis and dysfunctional adipose tissue in human hypertrophic obesity
Hammarstedt, A., Gogg, S., Hedjazifar, S., Nerstedt, A., & Smith, U. (2018) · Physiological Reviews · doi:10.1152/physrev.00034.2017 · Cited by 462
Harrison, D. E., Strong, R., Allison, D. B., Ames, B. N., Astle, C. M., Atamna, H., Fernandez, E., Flurkey, K., Javors, M. A., Nadon, N. L., et al. (2014) · Aging Cell · doi:10.1111/acel.12170 · Cited by 445
Cellular Senescence in Type 2 Diabetes: A Therapeutic Opportunity
Palmer, A. K., Tchkonia, T., LeBrasseur, N. K., Chini, E. N., Xu, M., & Kirkland, J. L. (2015) · Diabetes · doi:10.2337/db14-1820 · Cited by 423
Self-citationTargeted Elimination of Senescent Beta Cells Prevents Type 1 Diabetes
Thompson, P. J., Shah, A., Ntranos, V., Van Gool, F., Atkinson, M., & Bhushan, A. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.01.021 · Cited by 353
p16Ink4a-induced senescence of pancreatic beta cells enhances insulin secretion
Helman, A., Klochendler, A., Azazmeh, N., Gabai, Y., Horwitz, E., Anzi, S., Swisa, A., Condiotti, R., Granit, R. Z., Nevo, Y., et al. (2016) · Nature Medicine · doi:10.1038/nm.4054 · Cited by 351
Montero, J. C., Seoane, S., Ocaña, A., & Pandiella, A. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2616 · Cited by 298 · cited 1×
“D is a tyrosine kinase inhibitor used for treating cancers, but unlike most other tyrosine kinase inhibitors, it inhibits Src kinases (36).”
BackgroundCaron, M., Auclair, M., Donadille, B., Béréziat, V, Guerci, B., Laville, M., Narbonne, H., Bodemer, C., Lascols, O., Capeau, J., et al. (2007) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4402197 · Cited by 226 · cited 1×
“Similarly, individuals with some progeroid syndromes such as those associated with lamin-A (LMNA) mutations, which involve increased senescent cell burden, are also associated with lipodystrophy, metabolic syndrome, and diabetes (21, 22).”
BackgroundActivin A Plays a Critical Role in Proliferation and Differentiation of Human Adipose Progenitors
Zaragosi, L.-E., Wdziekonski, B., Villageois, P., Keophiphath, M., Maumus, M., Tchkonia, T., Bourlier, V., Mohsen-Kanson, T., Ladoux, A., Elabd, C., et al. (2010) · Diabetes · doi:10.2337/db10-0013 · Cited by 184
Self-citationFang, J., Yang, J., Wu, X., Zhang, G., Li, T., Wang, X., Zhang, H., Wang, C., Liu, G., & Wang, L. (2018) · Aging Cell · doi:10.1111/acel.12765 · Cited by 179
Discovery, development, and future application of senolytics: theories and predictions
Wissler Gerdes, E. O., Zhu, Y., Tchkonia, T., & Kirkland, J. L. (2020) · The FEBS Journal · doi:10.1111/febs.15264 · Cited by 160
Self-citationHannou, S. A., Wouters, K., Paumelle, R., & Staels, B. (2015) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2015.01.008 · Cited by 159 · cited 1×
“Polymorphisms in markers of cellular senescence, for example CDKN2A (which encodes p16), confer increased risk of developing type 2 diabetes and cardiovascular disease (20).”
BackgroundIncreased renal cellular senescence in murine high-fat diet: effect of the senolytic drug quercetin
Kim, S. R., Jiang, K., Ogrodnik, M., Chen, X., Zhu, X.-Y., Lohmeier, H., Ahmed, L., Tang, H., Tchkonia, T., Hickson, L. J., et al. (2019) · Translational Research · doi:10.1016/j.trsl.2019.07.005 · Cited by 139
Self-citationKuki, S., Imanishi, T., Kobayashi, K., Matsuo, Y., Obana, M., & Akasaka, T. (2006) · Circulation Journal · doi:10.1253/circj.70.1076 · Cited by 137 · cited 1×
“Cellular senescence is thought to play a role in development of insulin resistance and diabetic complications; however, the diabetic state can also cause formation of additional senescent cells, for example, through exposure to high glucose or lipid levels, which can themselves cause cellular senescence (10, 11).”
BackgroundSharma, A. K., Roberts, R. L., Benson, R. D., Pierce, J. L., Yu, K., Hamrick, M. W., & McGee-Lawrence, M. E. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00354 · Cited by 131 · cited 1×
“Navitoclax, another senolytic drug, can cause transient thrombocytopenia and direct cytotoxicity to osteoblasts (49).”
BackgroundTchkonia, T., Palmer, A. K., & Kirkland, J. L. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa728 · Cited by 129 · cited 1×
“Therefore, combinations of senolytic drugs (such as D+Q) target a broader range of senescent cell types than single agents, especially agents that have a single molecular target, which tend to target only a restricted range of senescent cells and may have more side effects than agents or combinations that act across S…”
BackgroundSelf-citationAblation of XP-V gene causes adipose tissue senescence and metabolic abnormalities
Chen, Y.-W., Harris, R. A., Hatahet, Z., & Chou, K.-M. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1506954112 · Cited by 86
Transplanting cells from old but not young donors causes physical dysfunction in older recipients
Wang, B., Liu, Z., Chen, V. P., Wang, L., Inman, C. L., Zhou, Y., Guo, C., Tchkonia, T., Rowe, D. W., Kuchel, G. A., et al. (2020) · Aging Cell · doi:10.1111/acel.13106 · Cited by 76 · cited 1×
“Once senescent cells form, the SASP can spread senescence in a paracrine or endocrine manner to previously normal local or distant cells (2, 9, 12-14).”
BackgroundSelf-citationLa Rosée, P., Martiat, P., Leitner, A., Klag, T., Müller, M. C., Erben, P., Schenk, T., Saussele, S., & Hochhaus, A. (2013) · Annals of Hematology · doi:10.1007/s00277-013-1769-2 · Cited by 50 · cited 1×
“In fact, an intermittent dosing schedule was shown to improve tolerability of D in patients with chronic myeloid leukemia (51).”
Background
Research works printed but not linked: 19
- Iske, 2020, Senolytics prevent mt-DNA-induced inflammation and promote the survival of aged organs following transplantation, Nat Commun., 11, 4289, 10.1038/s41467-020-18039-x · DOI · Paper page
- Coppé, 2010, The senescence-associated secretory phenotype: the dark side of tumor suppression, Annu Rev Pathol., 5, 99, 10.1146/annurev-pathol-121808-102144 · DOI · Paper page
- Minamino, 2009, A crucial role for adipose tissue p53 in the regulation of insulin resistance, Nat Med., 15, 1082, 10.1038/nm.2014 · DOI · Paper page
- Kim, 2020, Transplanted senescent renal scattered tubular-like cells induce injury in the mouse kidney, Am J Physiol Renal Physiol., 318, F1167, 10.1152/ajprenal.00535.2019 · DOI · Paper page
- Gustafson, 2019, Reduced subcutaneous adipogenesis in human hypertrophic obesity is linked to senescent precursor cells, Nat Commun., 10, 2757, 10.1038/s41467-019-10688-x · DOI · Paper page
- Garg, 2011, Clinical review#: lipodystrophies: genetic and acquired body fat disorders, J Clin Endocrinol Metab., 96, 3313, 10.1210/jc.2011-1159 · DOI · Paper page
- Kung, 2016, The role of the p53 tumor suppressor in metabolism and diabetes, J Endocrinol., 231, R61, 10.1530/JOE-16-0324 · DOI · Paper page
- Wu, 2018, Relevance of the p53-MDM2 axis to aging, Cell Death Differ., 25, 169, 10.1038/cdd.2017.187 · DOI · Paper page
- Huang, 2014, Role of p53 in preadipocyte differentiation, Cell Biol Int., 38, 1384, 10.1002/cbin.10334 · DOI
- Mitterberger, 2014, Adipogenic differentiation is impaired in replicative senescent human subcutaneous adipose-derived stromal/progenitor cells, J Gerontol A Biol Sci Med Sci., 69, 13, 10.1093/gerona/glt043 · DOI · Paper page
- Wang, 1995, Senescent human fibroblasts resist programmed cell death, and failure to suppress bcl2 is involved, Cancer Res., 55, 2284
- Olave, 2010, Upstream stimulatory factor-2 mediates quercetin-induced suppression of PAI-1 gene expression in human endothelial cells, J Cell Biochem., 111, 720, 10.1002/jcb.22760 · DOI · Paper page
- Bruning, 2013, Inhibition of mTOR signaling by quercetin in cancer treatment and prevention, Anticancer Agents Med Chem., 13, 1025, 10.2174/18715206113139990114 · DOI · Paper page
- Pignolo, 2020, Reducing senescent cell burden in aging and disease, Trends Mol Med., 26, 630, 10.1016/j.molmed.2020.03.005 · DOI · Paper page
- Christopher, 2008, Metabolism and disposition of dasatinib after oral administration to humans, Drug Metab Dispos., 36, 1357, 10.1124/dmd.107.018267 · DOI · Paper page
- Fox, 2017, The incidence and natural history of dasatinib complications in the treatment of chronic myeloid leukemia, Blood Adv., 1, 802, 10.1182/bloodadvances.2016003889 · DOI · Paper page
- Andres, 2018, Safety aspects of the use of quercetin as a dietary supplement, Mol Nutr Food Res., 62, 10.1002/mnfr.201700447 · DOI · Paper page
- Maher, 2015, How fisetin reduces the impact of age and disease on CNS function, Front Biosci (Schol Ed)., 7, 58, 10.2741/s425 · DOI · Paper page
- Kim, 2021, Metformin inhibits chronic kidney disease-induced DNA damage and senescence of mesenchymal stem cells, Aging Cell., 20, e13317, 10.1111/acel.13317 · DOI
Cited by
Cellular senescence and senolytics: the path to the clinic
Chaib, S., Tchkonia, T., & Kirkland, J. L. (2022) · Nature Medicine · doi:10.1038/s41591-022-01923-y · Cited by 1,134
Self-citationMechanisms and consequences of endothelial cell senescence
Bloom, S. I., Islam, M. T., Lesniewski, L. A., & Donato, A. J. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-022-00739-0 · Cited by 495
Tripathi, U., Nchioua, R., Prata, L. G. P. L., Zhu, Y., Gerdes, E. O. W., Giorgadze, N., Pirtskhalava, T., Parker, E., Xue, A., Espindola-Netto, J. M., et al. (2021) · Aging · doi:10.18632/aging.203560 · Cited by 88
“This includes elderly SARS-CoV-2 patients as well as younger patients with cellular senescence-linked conditions, such as obesity, diabetes, chronic respiratory, cardiovascular, and renal diseases, cancers, or a history of chemotherapeutic or radiation treatment, among others [5, 24, 25, 31, 41].”
Self-citationModulation of fracture healing by the transient accumulation of senescent cells
Saul, D., Monroe, D. G., Rowsey, J. L., Kosinsky, R. L., Vos, S. J., Doolittle, M. L., Farr, J. N., & Khosla, S. (2021) · eLife · doi:10.7554/elife.69958 · Cited by 71
Role of senescence in the chronic health consequences of COVID-19
Wissler Gerdes, E. O., Vanichkachorn, G., Verdoorn, B. P., Hanson, G. J., Joshi, A. Y., Murad, M. H., Rizza, S. A., Hurt, R. T., Tchkonia, T., & Kirkland, J. L. (2022) · Translational Research · doi:10.1016/j.trsl.2021.10.003 · Cited by 38
“Our ‘Threshold Theory of Senescent Cell Burden’ holds that once senescent cells accumulate and spread to a threshold that is higher than that which the immune system can clear, further senescent cell accumulation and accelerated age- or disease-related dysfunction can ensue.(46,74,103) Accumulation of senescent cells…”
Self-citation
Metadata
- Authors
- Palmer, A. K., Tchkonia, T., & Kirkland, J. L.
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2021-03-11
- Volume
- 162
- Issue
- 8
- ISSN
- 0013-7227 (ISSN-L)
- 1945-7170
- OpenAlex
- W3135850494
- Cited by
- 46
- References
- 44
- FWCI
- 4.44
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Funders
- National Institutes of Health (R37AG013925, P01AG062413, R01AG 072301, R01DK120292)
- Translational Geroscience Network (R33AG061456)
- Alzheimer’s Association Part the Cloud Program
- Robert and Arlene Kogod
- Connor Group
- Robert J. and Theresa W. Ryan
- Noaber Foundation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.